MétaCan
Menu
Back to cohort
Record W4416141158 · doi:10.25251/gsd1c102

Most Baricitinib Responders Achieved Full Scalp Hair Regrowth: Findings from Adult and Paediatric BRAVE-AA Trials

2025· article· W4416141158 on OpenAlexaff
Brett King, Justin Ko, Yutaka Shimomura, Melinda Gooderham, Rukhsar Chughtai, Samuel Ogwu, Najwa Somani, Lidia Rudnicka

Bibliographic record

VenueSKIN The Journal of Cutaneous Medicine · 2025
Typearticle
Language
FieldMedicine
TopicHair Growth and Disorders
Canadian institutionsSKiN Health
Fundersnot available
KeywordsScalpYoung adultClinical trialSeverity of illnessRandomized controlled trial

Abstract

fetched live from OpenAlex

Background Achievement of full scalp hair regrowth is an important outcome for patients with severe AA. Baricitinib is a selective JAK inhibitor that is approved in adults to treat severe AA and has now been studied in 257 adolescents (ages 12 to <18 years). In both populations, significant scalp hair regrowth (SALT score <20) was achieved in clinical trials. This analysis evaluates complete response thresholds of SALT score <10 and <5 among SALT score <20 responders, through Weeks (Wk) 36 and 52 in adolescent and adult populations, respectively. Methods Among BRAVE-AA1/2 (NCT03570749, NCT03899259) and BRAVE-AA-PEDS (NCT05723198) trials, baricitinib 4mg and 2mg responders (SALT score ≤20) were evaluated for achievement of SALT score ≤10 or ≤5 at Wk4, 8, 12, 16, 24, 36, and 52*. Results Among those patients treated with baricitinib 4mg, the proportion of adult responders who achieved SALT score <10 at Wk36 and Wk52 was 74.6% (150/201) and 75.0% (171/228); and the proportion in adolescents at Wk36 was 86.1% (31/36). Among those patients treated with baricitinib 4mg, the proportion of adults who achieved SALT score <5 at Wk36 and Wk52 was 55.2% (111/201) and 62.7% (143/228); and the proportion in adolescents at Wk36 was 61.1% (22/36). Some patients achieved these responses as early as Wk8 in both adult and adolescent populations.Among those patients treated with baricitinib 2mg, the proportion of adults who achieved SALT score <10 at W36 and W52 was 62.2% (51/82) and 71.0% (66/93); and the proportion in adolescents at W36 was 78.3% (18/23). Among those patients treated with baricitinib 2mg, the proportion of adults who achieved a SALT score <5 at W36 and W52 was 42.7% (35/82) and 47.3% (44/93); and the proportion in adolescents at W36 was 60.9% (14/23). Some patients achieved these responses as early as W8 in both adult and adolescent populations. Conclusion Baricitinib treated adult and adolescent patients who were responders (SALT score ≤20) had increasing depth of response over time with continued therapy, and the majority achieved full scalp hair regrowth. Footnote *Week 52 data is not yet available for the BRAVE-AA-PEDS trial.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.005
metaresearch head score (Gemma)0.006
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.005
Threshold uncertainty score0.028

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0050.006
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0000.001
Science and technology studies0.0000.000
Scholarly communication0.0010.001
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0030.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.014
GPT teacher head0.286
Teacher spread0.271 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueSKIN The Journal of Cutaneous MedicineSame topicHair Growth and DisordersFrench-language works237,207